STOCK TITAN

QIAGEN Announces Form 20-F Annual Report Filing for 2022 Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

QIAGEN N.V. (NYSE: QGEN) has filed its annual report on Form 20-F for the year ending December 31, 2022, with the U.S. Securities and Exchange Commission. The report is available for access on QIAGEN’s website. The company provides free printed copies of the annual report to shareholders upon request. QIAGEN is a leading provider of Sample to Insight solutions, offering technologies for isolating and processing biomolecules. As of December 31, 2022, the company employed approximately 6,200 people globally, serving over 500,000 customers across various sectors such as molecular diagnostics and academia.

Positive
  • Filed annual report for 2022, ensuring compliance with SEC regulations.
  • Continues to serve a broad customer base of over 500,000.
  • Employed approximately 6,200 employees, indicating robust operational capacity.
Negative
  • None.

VENLO, The Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2022, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website here.

QIAGEN will provide printed copies of the 2022 Annual Report to shareholders free of charge upon request. To obtain a printed copy of the 2022 Annual Report please use our contact form or send an email to ir@qiagen.com.

About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of December 31, 2022, QIAGEN employed approximately 6,200 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).

Category: Financial

Investor Relations

John Gilardi, +49 2103 29 11711

Phoebe Loh, +49 2103 29 11457

e-mail: ir@QIAGEN.com



Public Relations

Thomas Theuringer, +49 2103 29 11826

Daniela Eltrop, +49 2103 29 11676

e-mail: pr@QIAGEN.com

Source: QIAGEN N.V.

FAQ

What is the significance of QIAGEN's 2022 annual report filed on Form 20-F?

The filing demonstrates QIAGEN's compliance with SEC regulations and provides detailed financial data for investors.

Where can I access QIAGEN's 2022 annual report?

You can access the report on QIAGEN’s official website.

What does QIAGEN do?

QIAGEN provides Sample to Insight solutions, focusing on isolating and processing DNA, RNA, and proteins.

Who can request a printed copy of QIAGEN's annual report?

Shareholders can request a free printed copy of the annual report.

How many customers does QIAGEN serve?

QIAGEN serves over 500,000 customers worldwide.

QIAGEN N.V.

NYSE:QGEN

QGEN Rankings

QGEN Latest News

QGEN Stock Data

9.93B
217.27M
2.24%
87.87%
1.68%
Diagnostics & Research
Healthcare
Link
United States of America
Venlo